Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome
High resolution clustering of TP53 variants into functional classes correlates with cancer risk among germline variant carriers and identifies different phenotypes of the Li-Fraumeni Syndrome. Emilie Montellier, PhD (1), Nathanaël
Liquid Biopsy for Li-Fraumeni Syndrome Cancer Screening: Survey Study
We invite you to participate in a survey about your experiences receiving cancer screening for Li-Fraumeni Syndrome (LFS), and your thoughts about an upcoming clinical trial for people with LFS.Liquid
New Study: Navigating Dating & Relationships with LFS
Northwestern University is conducting a groundbreaking study focused on understanding patient perspectives on dating and disclosure to romantic partners for males diagnosed with Li-Fraumeni syndrome (LFS). Who are they looking
Additional cancer tumor types added to the Genetic Risk Assessment Guidelines
Breast, ovarian, pancreative, and prostate cancer have been added to the National Comprehensive Cancer Network Genetic/Familial High-Risk Assessment Guidelines following a recent expansion that includes colorectal, endometrial, and gastric
Benefits of Liquid Biopsy
CancerNetwork, an arm of the prestigious journal Oncology, joined LFSA at the 7th International LFS Association Symposium to report on the latest advances in LFS research and clinical therapies.
Potential of Metformin and LFS
CancerNetwork, an arm of the prestigious journal Oncology, joined LFSA at the 7th International LFS Association Symposium to report on the latest advances in LFS research and clinical therapies.
cfDNA Sequencing use in Li-Fraumeni syndrome
Presentations on advancements in early detection brought compelling research to light at the 7th International LFS Association Symposium. Trevor Pugh, PhD, FACMG, shared some early highlights from a randomized
Reducing barriers to care for those with Li-Fraumeni syndrome
The 7th International LFS Association Symposium delivered a powerful global collaboration intended to provide the best of care and hope to all of those with LFS and their families.
Whole Body MRI Anxiety
A unique aspect of the LFSA International Symposium is the intersection of LFS families among globally renowned medical and scientific experts. Lisa J. States, MD, shared with CancerNetwork her
Another survey opportunity: Risk-reducing mastectomy decision making process for adolescents and young adults with Li-Fraumeni Syndrome
Another invitation to participate in a study about the risk-reducing mastectomy decision making process for adolescents and young adults with Li-Fraumeni Syndrome: A team of researchers at the Icahn
Jenn Perry on WEEI for Jimmy Fund Telethon
LFSA founder Jenn Perry shares her family's LFS story and what motivates her to advocate for research and advancements to support those impacted by Li-Fraumeni syndrome. Jenn and her daughter
Breast Cancer Screening Post-Mastectomy Study
You are being invited to participate in a questionnaire study being run by Dana-Farber Cancer Institute. This study consists of a one-time questionnaire and is aimed at helping expand
Dollar For – Financial Assistance Webinar
Watch our latest webinar: Navigating Hospital Financial Assistance, presented by Dollar For. Hosted by the LFS Association, this webinar covers the essential topic of navigating hospital financial assistance programs,
Larry Ingrassia – A difficult and inspiring journey of discovery
Lawrence Ingrassia, author of A Fatal Inheritance: How a Family Misfortune Revealed a Deadly Medical Mystery, talks about the two-decades long journey by Dr. Joseph Fraumeni Jr. and Dr.
A Fatal Inheritance – How a Family Misfortune Revealed a Deadly Medical Mystery
Larry Ingrassia’s, A Fatal Inheritance, is the most comprehensive biography of Li-Fraumeni syndrome for the lay reader to date. Though this book reads like a riveting medical mystery, it is
New survey – vaccines for primary cancer prevention in adolescents & young adults
The Huntsman Cancer Institute in Utah is studying attitudes pertaining to vaccines for primary cancer prevention in adolescents and young adults with cancer predisposition syndromes. If you would like to
Congratulations to NCI’s Dr. Payal Kincha, co-chair of LFSA – India!
Dr. Payal Khincha, M.B.B.S., M.S.H.S., the inaugural Lasker Clinical Research Scholar in DCEG's Clinical Genetics Branch (CGB), whose expertise in diagnosing and managing Li-Fraumeni Syndrome (LFS) is reshaping the landscape
Liquid biopsy improves early cancer detection and diagnosis in patients with LFS
LFSA Medical Advisory Board Member Dr. David Malkin and his team at SickKids in Toronto continue to improve the lives of those with Li-Fraumeni syndrome! A recent article discusses
Hot off the press!!! Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry.
In 2017, not only did Dr. Christian Kratz launch our international chapter, LFSA – Germany, but he also founded the German Cancer Predisposition Syndrome Registry based at Hannover Medical
New publication! Cancer surveillance for patients with LFS in Brazil
Dr. Maria Isabel Achatz led a recent publication on the cost-effectiveness of Cancer surveillance for patients with LFS in Brazil using the Toronto Protocol screening guidelines. Brazil has a higher
NCI: Making Strides Toward Precision Medicine for Individuals with Li-Fraumeni Syndrome
Read about the advancements in LFS research that our team at the Division of Cancer Epidemiology and Genetics, Clinical Genetics Branch, have accomplished in their March 2022 news update.
Li-Fraumeni Syndrome Association Lauds Advancements in Classifying Hereditary Cancer Risks
HOLLISTON, MA -- The Li-Fraumeni Syndrome Association (LFSA), dedicated to furthering research and worldwide awareness of the inherited cancer predisposition disorder, celebrates new findings published in the renowned JAMA
Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium (and the LFS Association)
On November 2, 2010, the National Cancer Institute convened a workshop at the National Institutes of Health in Bethesda, Maryland, bringing together clinicians and scientists, as well as individuals from
